Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sidell, R. J.
Right arrow Articles by Clarke, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sidell, R. J.
Right arrow Articles by Clarke, K.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1110-1117, 2002
© 2002 by the American Diabetes Association, Inc.

Thiazolidinedione Treatment Normalizes Insulin Resistance and Ischemic Injury in the Zucker Fatty Rat Heart

Robert J. Sidell1, Mark A. Cole1, Nicholas J. Draper1, Martine Desrois1, Robin E. Buckingham2, and Kieran Clarke1

1 Department of Biochemistry, University of Oxford, Oxford, U.K.
2 GlaxoSmithKline, Harlow, Essex, U.K.

Obesity is associated with risk factors for cardiovascular disease, including insulin resistance, and can lead to cardiac hypertrophy and congestive heart failure. Here, we used the insulin-sensitizing agent rosiglitazone to investigate the cellular mechanisms linking insulin resistance in the obese Zucker rat heart with increased susceptibility to ischemic injury. Rats were treated for 7 or 14 days with 3 mg/kg per os rosiglitazone. Hearts were isolated and perfused before and during insulin stimulation or during 32 min low-flow ischemia at 0.3 ml · min-1 · grams wet wt-1 and reperfusion. D[2-3H]glucose was used as a tracer of glucose uptake, and phosphorus-31 nuclear magnetic resonance spectroscopy was used to follow energetics during ischemia. At 12 months of age, obese rat hearts were insulin resistant with decreased GLUT4 protein expression. During ischemia, glucose uptake was lower and depletion of ATP was greater in obese rat hearts, thereby significantly impairing recovery of contractile function during reperfusion. Rosiglitazone treatment normalized the insulin resistance and restored GLUT4 protein levels in obese rat hearts. Glucose uptake during ischemia was also normalized by rosiglitazone treatment, thereby preventing the greater loss of ATP and restoring recovery of contractile function to that of lean rat hearts. We conclude that rosiglitazone treatment, by normalizing glucose uptake, protected obese rat hearts from ischemic injury.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
S. Boudina and E. D. Abel
Diabetic Cardiomyopathy Revisited
Circulation, June 26, 2007; 115(25): 3213 - 3223.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. D. Hafstad, A. M. Khalid, O.-J. How, T. S. Larsen, and E. Aasum
Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1288 - E1294.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. An and B. Rodrigues
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Bertrand, A. Ginion, C. Beauloye, A. D. Hebert, B. Guigas, L. Hue, and J.-L. Vanoverschelde
AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H239 - H250.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. G. Poornima, P. Parikh, and R. P. Shannon
Diabetic Cardiomyopathy: The Search for a Unifying Hypothesis
Circ. Res., March 17, 2006; 98(5): 596 - 605.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. J. Murray, M. Panagia, D. Hauton, G. F. Gibbons, and K. Clarke
Plasma Free Fatty Acids and Peroxisome Proliferator-Activated Receptor {alpha} in the Control of Myocardial Uncoupling Protein Levels
Diabetes, December 1, 2005; 54(12): 3496 - 3502.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Lautamaki, K.E. J. Airaksinen, M. Seppanen, J. Toikka, M. Luotolahti, E. Ball, R. Borra, R. Harkonen, P. Iozzo, M. Stewart, et al.
Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease: A 16-Week Randomized, Double-Blind, Placebo-Controlled Study
Diabetes, September 1, 2005; 54(9): 2787 - 2794.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. S. Golfman, C. R. Wilson, S. Sharma, M. Burgmaier, M. E. Young, P. H. Guthrie, M. Van Arsdall, J. V. Adrogue, K. K. Brown, and H. Taegtmeyer
Activation of PPAR{gamma} enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E328 - E336.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken
Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats
J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Panagia, G. F. Gibbons, G. K. Radda, and K. Clarke
PPAR-{alpha} activation required for decreased glucose uptake and increased susceptibility to injury during ischemia
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2677 - H2683.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. L. Schiffrin
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1037 - H1043.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al.
PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1314 - H1323.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T.-L. Yue, W. Bao, J.-L. Gu, J. Cui, L. Tao, X.-L. Ma, E. H. Ohlstein, and B. M. Jucker
Rosiglitazone Treatment in Zucker Diabetic Fatty Rats Is Associated With Ameliorated Cardiac Insulin Resistance and Protection From Ischemia/Reperfusion-Induced Myocardial Injury
Diabetes, February 1, 2005; 54(2): 554 - 562.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. K. Mazumder, B. T. O'Neill, M. W. Roberts, J. Buchanan, U. J. Yun, R. C. Cooksey, S. Boudina, and E. D. Abel
Impaired Cardiac Efficiency and Increased Fatty Acid Oxidation in Insulin-Resistant ob/ob Mouse Hearts
Diabetes, September 1, 2004; 53(9): 2366 - 2374.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
Y. Shimoni, M. Chuang, E. D. Abel, and David. L. Severson
Gender-dependent attenuation of cardiac potassium currents in type 2 diabetic db/db mice
J. Physiol., March 1, 2004; 555(2): 345 - 354.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson
Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function
Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455.
[Abstract] [Full Text]


Home page
HypertensionHome page
M. Trivedi, A. Marwaha, and M. Lokhandwala
Rosiglitazone Restores G-Protein Coupling, Recruitment, and Function of Renal Dopamine D1A Receptor in Obese Zucker Rats
Hypertension, February 1, 2004; 43(2): 376 - 382.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. L. Schiffrin, F. Amiri, K. Benkirane, M. Iglarz, and Q. N. Diep
Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
Hypertension, October 1, 2003; 42(4): 664 - 668.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Scheuermann-Freestone, P. L. Madsen, D. Manners, A. M. Blamire, R. E. Buckingham, P. Styles, G. K. Radda, S. Neubauer, and K. Clarke
Abnormal Cardiac and Skeletal Muscle Energy Metabolism in Patients With Type 2 Diabetes
Circulation, June 24, 2003; 107(24): 3040 - 3046.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
C. J. Tack
Insulin Resistance and Acute Cardiovascular Complications
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 85 - 90.
[PDF]


Home page
DiabetesHome page
E. Aasum, A. D. Hafstad, D. L. Severson, and T. S. Larsen
Age-Dependent Changes in Metabolism, Contractile Function, and Ischemic Sensitivity in Hearts From db/db Mice
Diabetes, February 1, 2003; 52(2): 434 - 441.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.